Piper Sandler cuts Bristol Myers Squibb stock target to USD 78.00
Published on 10/26/2026 at 16:43 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWSAnalyst target and reporting date
- Piper Sandler cut its Bristol Myers Squibb target from USD 82.00 to USD 78.00 on October 26, 2026.
- Second-quarter revenue reached USD 12.97 billion, up 5.70 percent year over year.
- Bristol Myers Squibb stock traded at EUR 54.76 at Lang & Schwarz on October 26, 2026 at 4:36 p.m. CET.
- Bristol Myers Squibb is scheduled to report third-quarter results on October 29, 2026.
Bristol Myers Squibb (ISIN US1101221083) is facing a lower analyst target as Piper Sandler cut its price objective from USD 82.00 to USD 78.00 and kept an overweight rating in a research note dated October 26, 2026, as reported by MarketBeat. Piper Sandler's revised target is 27.33 percent above the NYSE price of USD 61.26 at 11:42 a.m. EDT on October 26, 2026. At Lang & Schwarz, Bristol Myers Squibb traded at EUR 54.76 on October 26, 2026 at 4:36 p.m. CET.
Second-quarter revenue provides context
Bristol Myers Squibb reported USD 12.97 billion in second-quarter revenue for the period ended June 30, 2026, compared with USD 11.74 billion expected by analysts. The company also reported diluted earnings per share of USD 1.62 for the quarter, while a separate market report cited adjusted earnings per share of USD 2.04 and revenue growth of 5.70 percent from the prior year. The reported revenue and earnings figures are carried by MarketBeat.
EUR 54.76 in euro trading
The primary listing is on the NYSE, where the stock was trading at USD 61.26 on October 26, 2026 at 11:42 a.m. EDT. Its 52-week range was USD 42.52 to USD 68.64, placing the current US quotation USD 7.38 below the high and USD 18.74 above the low. Bristol Myers Squibb's market capitalization was USD 125.1 billion, and its price-to-earnings ratio was 13.49 on the same date.
Valuation meets October 29 results
The next scheduled reporting date is October 29, 2026. A market calendar lists third-quarter revenue at a consensus USD 12.73 billion and consensus earnings per share at USD 1.28 for that report, according to Moomoo. That estimate gives the October 29 event a concrete benchmark against the USD 12.97 billion reported for the second quarter.
Peer valuation remains divided
At the October 26, 2026 US quotation, AbbVie had a market capitalization of USD 506.7 billion and a price-to-earnings ratio of 80.78, while Pfizer had a market capitalization of USD 170.0 billion and a ratio of 39.40. Bristol Myers Squibb therefore combines a USD 125.1 billion market value with a lower 13.49 ratio than both comparison companies.
Target reset before results
The target reduction gives investors a fresh valuation marker before the October 29 results, while the second-quarter revenue comparison supplies the operating benchmark.
The stock traded at EUR 54.76 at Lang & Schwarz on October 26, 2026 at 4:36 p.m. CET.
The further course of trading is shown by the continuously updated real-time quote of Bristol Myers Squibb stock.
Bristol Myers Squibb stock at a glance
- Company: Bristol-Myers Squibb Company
- ISIN: US1101221083
- Ticker: BMY
- Primary exchange: NYSE
- Price Lang & Schwarz (as of October 26, 2026, 4:36 p.m. CET): EUR 54.76
- Market capitalization: USD 125.1 billion (as of October 26, 2026)
- 52-week range: USD 42.52-68.64 (as of October 26, 2026)
- Sector / Industry: Health Care / Biopharmaceuticals
Market context: Market report S&P 500.
